WASHINGTON, Feb. 20, 2018 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly dividend of $0.16 per share payable on April 27, 2018 to holders of record on March 29, 2018.
ABOUT DANAHER Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in some of the most demanding and attractive industries, including health care, environmental and industrial. With more than 20 operating companies, Danaher's globally diverse team of approximately 67,000 associates is united by a common culture and operating system, the Danaher Business System. For more information, please visit www.danaher.com.
MiniTool Software Limited has released a new version of its video making program ? MiniTool MovieMaker 7.3.0 with brand-new resources to decorate videos effortlessly....
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, today announced its participation in the 'Runes Incubator.' This program, initiated by OnePiece Labs and supported by Merlin Chain and Franklin Templeton,...
SK hynix Inc. (or "the company", www.skhynix.com) announced today that it has recently signed a memorandum of understanding with TSMC for collaboration to...
ShipSaving, a fast-growing shipping platform recognized in the 2023 Deloitte Technology Fast 500tm, proudly announces a groundbreaking development as the first multi-carrier shipping company to offer UPS no-label shipping. This innovative feature...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...
